Cidara Therapeutics, Inc. - Common Stock (CDTX)

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also began coverage of the stock, assigning it an Overweight rating and setting a price target of $200.

The company earned an important fast-track review designation for a pipeline medication.

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.

The company could have quite a winner on its hands with its most advanced pipeline drug.

The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months.

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

The midstage study hit all its goals, representing a "best case" scenario, according to one analyst.

Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.